CTI Clinical Trial and Consulting Services Announces Acquisition of S2 Statistical Solutions

(S2). S2, a health outcomes and health economics organization, focuses on the power of analytics through data mining and economic research. S2 specializes in generating and interpreting evidence from large databases and then publishing it in the most effective, high-impact venues, including various peer reviewed publications. S2 has been partnering with pharmaceutical, medical device, and diagnostic companies for over a decade, providing innovative outcome and economic analyses, models, visualization programs, systematic literature reviews, and meta analyses. Dr. Candace Gunnarsson, the founder of S2, will be joining CTI along with her entire team.

“I am very excited to combine forces with CTI and I know that we will be able to achieve great things together. Our principles, work ethic and expertise truly complement the CTI Team,” states Dr. Candace Gunnarsson, President of S2.

According to Lynn Fallon, Executive Vice President and President, Consulting Services at CTI, “The S2 team members are incredibly accomplished with top-ranked scientists, health economists, and statisticians, and will join Dr. William Irish, CTI’s Vice President of Health Outcomes and Biostatistics, as well as the rest of our team at CTI. We firmly believe that health outcomes and economics are critically important to both our biotechnology and pharmaceutical clients. This merger strengthens our service offerings from the early development stages of drugs and devices through Phase 3 and commercialization. Investors often require companies to build economic models to provide product valuation, even in early development. Health economics is also proving particularly important to the many orphan disease programs that CTI is leading.”

The terms of the acquisition were not disclosed. Plante Moran and Fifth Third Bank provided support to CTI, while Graydon, Head and Ritchey assisted S2.